Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-(pyridin-3-yl)-1,3-thiazol-2-yl)amino)phenyl)benzamide
2. Ab 1010
3. Ab-1010
4. Ab1010
5. Kinavet
6. Kinavet Ca-1
7. Masatinib
8. Masican
9. Masitinib
10. Masitinib Mesilate
11. Masitinib Methanesulfonate
12. Masivet
13. Masiviera
1. 1048007-93-7
2. Masitinib (mesylate)
3. Masivet
4. Ab-1010 Mesylate
5. Masitinib Mesilate
6. Ab 1010 Mesylate
7. Kinavet
8. Zk89eg3a18
9. Masican
10. Masiviera
11. 4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-pyridin-3-yl-1,3-thiazol-2-yl)amino)phenyl)benzamide Methanesulfonate
12. 4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-pyridin-3-yl-1,3-thiazol-2-yl)amino)phenyl)benzamide Methanesulphonate
13. 4-(4-methyl-piperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide Methanesulfonate
14. Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-n-(4-methyl-3-((4-(3-pyridinyl)-2-thiazolyl)amino)phenyl)-, Methanesulfonate (1:1)
15. Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-n-(4-methyl-3-((4-(3-pyridinyl)-2-thiazolyl)amino)phenyl)-, Methanesulphonate (1:1)
16. 4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide Mesylate
17. 928671-85-6
18. Methanesulfonic Acid;4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide
19. Unii-zk89eg3a18
20. Masitinibmesylate
21. Schembl1096348
22. Dtxsid70146747
23. Bcp30695
24. Ex-a3996
25. Masitinib Mesilate [who-dd]
26. Yrb00793
27. Hy-10209a
28. Cs-1593
29. Masitinib Mesylate [green Book]
30. Masitinib Methanesulfonate [mi]
31. Sb14845
32. Ac-30896
33. As-56731
34. Ft-0707180
35. C71194
36. Masitinib Mesylate [ema Epar Veterinary]
37. A927557
38. Q27295645
39. Ab1010 Mesylate;ab-1010 Mesylate;ab 1010 Mesylate
40. Masitinib Mesylate Salt; Masitinib Mesilate;ab 1010 Mesylate Pound>>ab1010 Mesylate Pound>>ab-1010 Mesylate
41. N-(4-methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide Methanesulfonate
42. N-(4-methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide Methanesulfonate;
| Molecular Weight | 594.8 g/mol |
|---|---|
| Molecular Formula | C29H34N6O4S2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 7 |
| Exact Mass | 594.20829593 g/mol |
| Monoisotopic Mass | 594.20829593 g/mol |
| Topological Polar Surface Area | 164 Ų |
| Heavy Atom Count | 41 |
| Formal Charge | 0 |
| Complexity | 788 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Treatment of amyotrophic lateral sclerosis.
Treatment of mastocytosis
Treatment of non resectable locally advanced or metastatic pancreatic cancer
Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST)
Treatment of non-resectable dog mast-cell tumours (grade 2 or 3) with confirmed mutated c-KIT tyrosine-kinase receptor.
Treatment of mastocytosis
Treatment of gastro-intestinal stromal tumours
Treatment of amyotrophic lateral sclerosis
L01XE22
L01XE22
L01XE
L01XE
QL01XE90
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Masitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Masitinib, including repackagers and relabelers. The FDA regulates Masitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Masitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Masitinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Masitinib supplier is an individual or a company that provides Masitinib active pharmaceutical ingredient (API) or Masitinib finished formulations upon request. The Masitinib suppliers may include Masitinib API manufacturers, exporters, distributors and traders.
click here to find a list of Masitinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Masitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Masitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Masitinib GMP manufacturer or Masitinib GMP API supplier for your needs.
A Masitinib CoA (Certificate of Analysis) is a formal document that attests to Masitinib's compliance with Masitinib specifications and serves as a tool for batch-level quality control.
Masitinib CoA mostly includes findings from lab analyses of a specific batch. For each Masitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Masitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Masitinib EP), Masitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Masitinib USP).
LOOKING FOR A SUPPLIER?
